Alessandro Fatatis
Overview
Explore the profile of Alessandro Fatatis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1382
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oyende Y, Taus L, Fatatis A
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858071
Since its discovery, IL-1β has taken center stage as a key mediator of a very broad spectrum of diseases revolving around immuno-mediated and inflammatory events. Predictably, the pleiotropic nature of...
2.
DiNatale A, Worrede A, Iqbal W, Marchioli M, Toth A, Sjostrom M, et al.
Cancer Res Commun
. 2022 Dec;
2(12):1545-1557.
PMID: 36561929
We report the inverse association between the expression of androgen receptor (AR) and interleukin-1beta (IL-1β) in a cohort of patients with metastatic castration resistant prostate cancer (mCRPC). We also discovered...
3.
DiNatale A, Castelli M, Nash B, Meucci O, Fatatis A
J Cancer
. 2022 Sep;
13(11):3160-3176.
PMID: 36118530
Tumor-initiating cells (TICs) are a rare sub-population of cells within the bulk of a tumor that are major contributors to tumor initiation, metastasis, and chemoresistance. TICs have a stem-cell-like phenotype...
4.
DiNatale A, Kaur R, Qian C, Zhang J, Marchioli M, Ipe D, et al.
Oncogene
. 2022 Jan;
41(9):1337-1351.
PMID: 34999735
Metastasis-initiating cells (MICs) display stem cell-like features, cause metastatic recurrences and defy chemotherapy, which leads to patients' demise. Here we show that prostate and breast cancer patients harbor contingents of...
5.
DiNatale A, Fatatis A
Adv Exp Med Biol
. 2020 Jan;
1210:171-184.
PMID: 31900910
The propensity of prostate cancer cells to seed the skeleton and then progress into clinically relevant metastatic tumors is widely recognized and a major cause of morbidity and mortality for...
6.
Worrede A, Meucci O, Fatatis A
Pharmacol Ther
. 2019 Mar;
199:117-128.
PMID: 30877019
Here we propose that therapeutic targeting of circulating tumor cells (CTCs), which are widely understood to be the seeds of metastasis, would represent an effective strategy towards limiting numerical expansion...
7.
Qian C, Worrede-Mahdi A, Shen F, DiNatale A, Kaur R, Zhang Q, et al.
Mol Cancer Res
. 2018 Aug;
16(12):1844-1854.
PMID: 30115759
Circulating tumor cells (CTCs) are commonly detected in the systemic blood of patients with cancer with metastatic tumors. However, the mechanisms controlling the viability of cancer cells in blood and...
8.
Rodriguez-Bravo V, Pippa R, Song W, Carceles-Cordon M, Dominguez-Andres A, Fujiwara N, et al.
Cell
. 2018 Aug;
174(5):1200-1215.e20.
PMID: 30100187
Nuclear pore complexes (NPCs) regulate nuclear-cytoplasmic transport, transcription, and genome integrity in eukaryotic cells. However, their functional roles in cancer remain poorly understood. We interrogated the evolutionary transcriptomic landscape of...
9.
Jiao X, Velasco-Velazquez M, Wang M, Li Z, Rui H, Peck A, et al.
Cancer Res
. 2018 Jan;
78(7):1657-1671.
PMID: 29358169
The functional significance of the chemokine receptor CCR5 in human breast cancer epithelial cells is poorly understood. Here, we report that CCR5 expression in human breast cancer correlates with poor...
10.
Ju X, Jiao X, Ertel A, Casimiro M, Di Sante G, Deng S, et al.
Cancer Res
. 2016 Sep;
76(22):6723-6734.
PMID: 27634768
Proteomic analysis of castration-resistant prostate cancer demonstrated the enrichment of Src tyrosine kinase activity in approximately 90% of patients. Src is known to induce cyclin D1, and a cyclin D1-regulated...